312 related articles for article (PubMed ID: 27666759)
1. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
[TBL] [Abstract][Full Text] [Related]
2. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
[TBL] [Abstract][Full Text] [Related]
3. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
Sugatani T
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
[TBL] [Abstract][Full Text] [Related]
4. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Agapova OA; Fang Y; Sugatani T; Seifert ME; Hruska KA
Kidney Int; 2016 Jun; 89(6):1231-43. PubMed ID: 27165838
[TBL] [Abstract][Full Text] [Related]
5. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
6. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
[TBL] [Abstract][Full Text] [Related]
7. Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.
Cejka D; Parada-Rodriguez D; Pichler S; Marculescu R; Kramer I; Kneissel M; Gross T; Reisinger A; Pahr D; Monier-Faugere MC; Haas M; Malluche HH
Kidney Int; 2016 Oct; 90(4):828-34. PubMed ID: 27528549
[TBL] [Abstract][Full Text] [Related]
8. Relationship between aortic mineral elements and osteodystrophy in mice with chronic kidney disease.
Matsumoto T; Fukushima S; Kanasaki T; Hagino S
Biol Trace Elem Res; 2012 Dec; 150(1-3):278-84. PubMed ID: 22700181
[TBL] [Abstract][Full Text] [Related]
9. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome.
Davies MR; Lund RJ; Mathew S; Hruska KA
J Am Soc Nephrol; 2005 Apr; 16(4):917-28. PubMed ID: 15743994
[TBL] [Abstract][Full Text] [Related]
10. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
Hruska KA; Sugatani T; Agapova O; Fang Y
Bone; 2017 Jul; 100():80-86. PubMed ID: 28119179
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease.
Tani T; Orimo H; Shimizu A; Tsuruoka S
Sci Rep; 2017 May; 7(1):2233. PubMed ID: 28533541
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
[TBL] [Abstract][Full Text] [Related]
13. Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.
Lu CL; Shyu JF; Wu CC; Hung CF; Liao MT; Liu WC; Zheng CM; Hou YC; Lin YF; Lu KC
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30149605
[TBL] [Abstract][Full Text] [Related]
14. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
[TBL] [Abstract][Full Text] [Related]
15. Bisphophonates in CKD patients with low bone mineral density.
Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.
González EA; Lund RJ; Martin KJ; McCartney JE; Tondravi MM; Sampath TK; Hruska KA
Kidney Int; 2002 Apr; 61(4):1322-31. PubMed ID: 11918739
[TBL] [Abstract][Full Text] [Related]
17. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
[TBL] [Abstract][Full Text] [Related]
18. Dentoalveolar Alterations in an Adenine-Induced Chronic Kidney Disease Mouse Model.
Mohamed FF; Amadeu de Oliveira F; Kinoshita Y; Yalamanchili RR; Eltilib LA; Andras NL; Narisawa S; Tani T; Chu EY; Millán JL; Foster BL
J Bone Miner Res; 2023 Aug; 38(8):1192-1207. PubMed ID: 37191192
[TBL] [Abstract][Full Text] [Related]
19. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.
Fang Y; Ginsberg C; Sugatani T; Monier-Faugere MC; Malluche H; Hruska KA
Kidney Int; 2014 Jan; 85(1):142-50. PubMed ID: 23884339
[TBL] [Abstract][Full Text] [Related]
20. Role of TGF-β in a mouse model of high turnover renal osteodystrophy.
Liu S; Song W; Boulanger JH; Tang W; Sabbagh Y; Kelley B; Gotschall R; Ryan S; Phillips L; Malley K; Cao X; Xia TH; Zhen G; Cao X; Ling H; Dechow PC; Bellido TM; Ledbetter SR; Schiavi SC
J Bone Miner Res; 2014; 29(5):1141-57. PubMed ID: 24166835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
